Archive for the ‘Activism’ Category

The History Of Lyme Disease – Dr. Burrascano

https://www.ilads.org/dr-burrascano-happy-holidays/?  Approx. 43 Min.

The History of Lyme Disease

Dr. Burrascano explains and debunks much of what is accepted and blindly promoted in main-stream medicine about Lyme.

For a summary of the video go here.  Go here for an article that presents a bird’s-eye view of the entire issue.

He also shares what he discovered worked with patients, including himself, often by trial and error.

Important takeaways:

  • Burrascano found that blood levels of various drugs in some patients was low or even undetectable.  In other words, the level of doxycycline in the blood for instance, was too low to kill anything, which helps explain why some fail antibiotic therapy.  (Scroll to 17:30 for this information.)  He also cringes because the CDC guidelines state all patients should receive 200mg of doxycycline, which sets some patients up for failure.  Doctors should do blood levels on patients to determine if it’s working.
  • He, as well as ILADS, recommends being symptom-free for 2-4 months before stopping treatment.  Then, wait until symptoms return and go back on treatment.  This is called Cycling.  He found that cycling 3-4 times typically worked for most patients.  Ironically, the 3rd cycle yielded the worst herx.  Pam Weintraub wrote about this in, “Cure Unknown:  Inside the Lyme Disease Epidemic,” way back in the 90’s, yet few doctors do this.
Please share this with family, friends, doctors, and researchers.

Widespread Inflammation in Brains of Those With Fibromyalgia

https://neurosciencenews.com/inflammation-fibromyalgia-9925/?

Widespread Inflammation in Brains of Those with Fibromyalgia

Summary: A new study reveals elevated glial activation in the brains of those with fibromyalgia.

Source: Mass General.

A study by Massachusetts General Hospital (MGH) researchers – collaborating with a team at the Karolinska Institutet in Sweden – has documented for the first time widespread inflammation in the brains of patients with the poorly understood condition called fibromyalgia. Their report has been published online in the journal Brain, Behavior and Immunity.

“We don’t have good treatment options for fibromyalgia, so identifying a potential treatment target could lead to the development of innovative, more effective therapies,” says Marco Loggia, PhD, of the MGH-based Martinos Center for Biomedical Imaging, co-senior author of the report. “And finding objective neurochemical changes in the brains of patients with fibromyalgia should help reduce the persistent stigma that many patients face, often being told their symptoms are imaginary and there’s nothing really wrong with them.”

Characterized by symptoms including chronic widespread pain, sleep problems, fatigue, and problems with thinking and memory, fibromyalgia affects around 4 million adults in the U.S., according to the Centers for Disease Control and Prevention. Previous research from the Karolinska group led by Eva Kosek, MD, PhD, co-senior author of the current study, suggested a potential role for neuroinflammation in the condition – including elevated levels of inflammatory proteins in the cerebrospinal fluid – but no previous study has directly visualized neuroinflammation in fibromyalgia patients.

A 2015 study by Loggia’s team used combined MR/PET scanning to document neuroinflammation – specifically activation of glial cells – in the brains of patients with chronic back pain. Hypothesizing that similar glial activation might be found in fibromyalgia patients as well, his team used the same PET radiopharmaceutical, which binds to the translocator protein (TSPO) that is overexpressed by activated glial cells, in their study enrolling 20 fibromyalgia patients and 14 control volunteers.

At the same time, Kosek’s team at Karolinska had enrolled a group of 11 patients and an equal number of control participants for a similar study with the TSPO-binding PET tracer. Since that radiopharmaceutical binds to two types of glial cells – microglia and astrocytes – they also imaged 11 patients, 6 who had the TSPO imaging and 5 others, and another 11 controls with a PET tracer that is thought to bind preferentially to astrocytes and not to microglia. At both centers, participants with fibromyalgia completed questionnaires to assess their symptoms. When the MGH team became aware of the similar investigation the Karolinska group had underway, the teams decided to combine their data into a single study.

a brain scan

The results from both centers found that glial activation in several regions of the brains of fibromyalgia patients was significantly greater than it was in control participants. Compared to the MGH team’s chronic back pain study, TSPO elevations were more widespread throughout the brain, which Loggia indicates corresponds to the more complex symptom patterns of fibromyalgia. TSPO levels in a structure called the cingulate gyrus – an area associated with emotional processing where neuroinflammation has been reported in patients with chronic fatigue syndrome – corresponded with patients reported levels of fatigue. The Karolinska team’s studies with the astrocyte-binding tracer found little difference between patients and controls, suggesting that microglia were primarily responsible for the increased neuro-inflammation in fibromyalgia patients.

“The activation of glial cells we observed in our studies releases inflammatory mediators that are thought to sensitize pain pathways and contribute to symptoms such as fatigue,” says Loggia, an assistant professor of Radiology at Harvard Medical School. “The ability to join forces with our colleagues at Karolinska was fantastic, because combining our data and seeing similar results at both sites gives confidence to the reliability of our results.”

Original Research: Open access research for “Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation” by Daniel S.Albrecht, Anton Forsberg, Angelica Sandström, Courtney Bergan, Diana Kadetoff, Ekaterina Protsenko, Jon Lamp, Yvonne C. Lee, Caroline Olgart Höglund, Ciprian Catana, Simon Cervenka, Oluwaseun Akeju, Mats Lekander, George Cohen, Christer Halldin, Norman Taylor, Minhae Kim, Jacob M. Hooker, Robert R. Edwards, Vitaly Napadowa, Eva Kosek, and Marco L.Loggia in Brain, Behavior and Immunity. Published September 14 2018.
doi:10.1016/j.bbi.2018.09.018

_________________
**Comment**
Many Lyme/MSIDS patients are initially diagnosed with fibromyalgia.
https://www.lymedisease.org/lyme-sci-fibro/  In this informative article you will read about how Rheumatologist, Dr. Miller, became a Lyme activist due to his daughter-in-law’s misdiagnosis of fibromyalgia.
He believes all patients who have been given a diagnosis of a neurodegenerative disease—including ALS, MS, lupus, and fibromyalgia—should be evaluated for Lyme disease.

Almost all of these diseases are accompanied by pain, fatigue, sleep issues, cognitive issues, headache, numbness and tingling.

And, according to a survey of over 4000 patients with Lyme disease,

“roughly 20% of those with chronic Lyme disease were initially misdiagnosed with a neurologic disease including MS, ALS, Parkinson’s and multiple systems atrophy.”

Dr. Miller’s 4-part Lyme series:  https://madisonarealymesupportgroup.com/2017/05/11/dr-al-miller-lyme-disease-series/

Interview with Dr. Miller:  https://madisonarealymesupportgroup.com/2017/10/13/dr-miller-a-new-perspective-on-lyme-disease/

 

 

What I’ve Learned Reporting About Lyme Disease, a Contested Illness

https://www.cjr.org/analysis/lyme-disease-contested-illness-empathy.php

What I’ve learned reporting about Lyme disease, a contested illness

As Jeff Wheelwright began researching his book about Gulf War Syndrome, he planned to speak to suffering veterans and medical experts who were skeptical those ailments were real. But the first veteran Wheelwright interviewed flipped the script. “What is the goal of your book?” the man asked. “Does it lean more toward the veterans’ side of the house, or the other side?”

Wheelwright’s experience resonated with me. When I began reporting on Lyme disease in 2017 for a series for a Boston National Public Radio station, I quickly learned my attempt at impartiality was naive. I’m a physician, and in medical school I learned a strong majority of physicians and scientists view this common tick-borne illness as relatively straightforward and treatable by antibiotics. Many people and some doctors, however, hold that a chronic, treatment-resistant form of the disease is also widespread—a claim dismissed by the large majority of infectious disease experts.

I’m also a social scientist, so I saw Lyme fitting in with numerous other “contested illnesses,” from Gulf War Syndrome to chronic fatigue syndrome to Morgellons. Contested illnesses have uncertain causes, unclear treatments, and disputed medical, legal and cultural definitions. Lodged where politics, intense emotions, and science converge, these are the “illnesses you have to fight to get,” as one study termed them, because whether such illnesses even exist is hotly debated.

Covering Lyme and other contested illnesses, therefore, requires that reporters navigate a minefield of competing expertise and experiences. A misstep could dismiss suffering patient-activists; it could also uncritically report claims unsupported by the scientific process. But careful reporting and writing can play a crucial role in helping patients and scientists alike sort through rumor and anecdote to understand the science of contested illness in plain language.

For the seven-part series, I spent days reporting in Cape Cod and eastern France, interviewing public health officials finding innovative ways to combat ticks, scientists trying to understand the disease and its spread, and patients and their family members who struggle with tick-borne illnesses. I spent hours reading websites of associations and “Lyme literate” patient-advocacy groups.

Lyme experts and patients often asked my opinion on non-standard treatments such as essential oils or long-term antibiotics, questions designed to reveal my bias. I worried anything I said would shatter my interviewee’s trust.

Early on, I listened to patients and experts on social media and blogs to understand their suffering and frustration with a medical system that did not help them and made them feel even worse by denying them a diagnosis. I also spoke to Abigail Dumes, a colleague anthropologist researching Lyme. Her years of ethnographic experience with doctors and patients were like a Cliff’s Notes, illuminating the major debates, key figures, and landmines right at the start.

Journalists without time for background research can stumble onto one of those landmines. In 2011, reporter David Tuller wrote about a trial exploring the benefit of exercise therapy for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). “Not knowing any of the background, I took the study at face value,” he later wrote.

The backlash was immediate. Numerous ME/CFS sufferers wrote in, concerned about the trial’s numerous methodological problems. Compelled to dig deeper, Tuller eventually penned a 15,000-word critique of the trial’s methodology. (The controversy continues today.)

Picking the right story angle is also critical to avoid repeating stereotypes and report beyond the controversy. A 2016 Aeon article highlighted clichés about vaccine-rejecting parents—different than contested illness, but with a similar political valence pitting regular people against medical consensus. Those stories shared a formula, wrote Maggie Koerth-Baker: “The parents fear vaccines. The scientists say those fears are unwarranted. Wash, rinse, repeat.”

Exposing clichés helped Koerth-Baker write beyond them. She found that parents often accepted vaccine science but chose not to risk side effects, no matter how rare. Parents’ values—not their grasp of facts—determined their stance.

Lyme reporting also has repetitive narratives: a debilitated patient suffering from a mysterious, recurrent illness facing off against numerous skeptical doctors who told them their symptoms were “all in their head.” I read numerous stories, often about celebrities with Lyme, detailing how they saw countless doctors, all of whom misdiagnosed them until one finally found the “correct” diagnosis. Reporters usually do not question the narrative and how that diagnosis was finally made, or how all those other doctors could have gotten it wrong. The intricacies of Lyme diagnostic testing are complex, but journalists often overstate the foibles, saying it is “impossible” to detect the bacteria or blood testing is unreliable.

So I focused on what seemed like key questions that still lacked answers, such as why we know so little about preventing Lyme disease, or why, despite growing numbers of ticks, local public health efforts remained so fragmented and limited to educating people about bug repellent and tick checks. When I focused on how a treatment center took a new perspective on helping suffering patients, part of the story was how they tried, but ultimately failed, to avoid taking sides in the debate.

Journalists are in a unique position to shape how people view contested illnesses and the people suffering from them. It is both vital and possible to be simultaneously empathetic and accurate. “I try not to be a cruel person,” says Amy Maxmen, a senior reporter for Nature who has written about ME/CFS. “I’m going to take them at their word when they say they’re going through something terrible.”

Some people with contested illnesses might offer their treatment stories as unimpeachable; still, providing context, like the strength of the evidence for or against them, plus their cost and potential side effects, is crucial to avoid spreading misinformation.

And Lyme patients were clearly suffering with something, even if it wasn’t clear what. I would try to validate that suffering in interviews, then stay quiet and listen. I’d ask probing questions if my interviewee veered toward the conspiratorial, but would not derail the interview with a debate, preferring to follow up later after I was able to dig more thoroughly through the literature.

The same went for treatments. Lyme experts and patients often asked my opinion on non-standard treatments such as essential oils or long-term antibiotics, questions designed to reveal my bias. I worried anything I said would shatter my interviewee’s trust.

Maxmen does not simply report anecdotes about successful treatments, like coffee enemas, that are commonplace for ME/CFS. Many non-standard treatments for Lyme are well studied with most not shown to help while some can even cause harm. Some people with contested illnesses might offer their treatment stories as unimpeachable; still, providing context, like the strength of the evidence for or against them, plus their cost and potential side effects, is crucial to avoid spreading misinformation.

The usual caveats for science journalists apply doubly for writing about contested illnesses: Avoid false balance (“on the one hand”, “on the other”) when there is an established scientific consensus. Maintain healthy skepticism, and take heed the lessons of media coverage of past controversial illnesses such as hysteria or neurasthenia.

No matter how carefully a journalist writes a story, her work still may be undone—by an editor who wants an easy takeaway, or poorly chosen art, or hastily written headlines, captions, and social media posts that oversimplify the story.

I was lucky. At WBUR I had a generous word count, multiple pieces in a series to provide context, and a supportive editor who sought my input in headlines and radio segments. Her experience with Lyme and the potential for backlash meant we both were extra careful.

Still, we had to be prepared for angry reactions. In the past, I ignored comments on my stories. Then I read the social science literature suggesting that unchallenged misinformation will persist.  Now I try to respond, sometimes even to inflammatory comments, emphasizing open mindedness, empathy to those suffering, and avoiding bias. My editor often pitched in, as a team approach helped distribute the extra time and patience required.

I found many arguments about Lyme focus on studies that support their conclusions without even-handedly assessing the quality of all the data out there. I emphasize quality to point out why we should trust randomized, controlled studies more than anecdotal evidence or low-quality studies. But I also emphasize points of agreement, like how we all want to do a better job of being empathetic to suffering people with unclear diagnoses. Stories about contested illness test the skills and mettle of journalists, but, at a time of fake news and rampant misinformation, getting these stories right is more important than ever.

David Scales is an Assistant Professor of Medicine at Weill Cornell Medical College. He was a special correspondent for WBUR, and has written for Aeon, Undark, and CommonHealth about issues where social sciences and health intersect. Reporting for his “Losing to Lyme” project was supported by the Pulitzer Center for Crisis Reporting. He can be found on Twitter @davidascales.

 

For the Losing to Lyme Series:  https://www.wbur.org/commonhealth/tag/losing-to-lyme

 

 

 

Research News: Dr. Steven Phillips

https://www.stevenphillipsmd.com

Research News

In the link above, Dr. Steven Phillips talks about two research projects he is working on.

  1. The first project is a joint venture between Duke, Johns Hopkins, and Tulane which was fully funded by the Steven and Alexandra Cohen Foundation. The goal is to use a specialized high thoughput proteomics platform to find new drugs to treat Lyme and bartonella. It’s the same precision medicine technology used to find drugs for cancer and HIV, only this time it’s finally turned toward eradicating Lyme and Bartonella. And we already have lots of initial hits!
  2. The second project is further along thanks to funding from Bay Area Lyme Foundation. We’ve moved forward with starting drug formulation and laboratory testing. I’m working alongside Dr. Neil Spector of Duke, Dana Parish, Dr. Ed Breitschwerdt and his team from Galaxy Diagnostics and NC State, and too many others to list here. We’re developing what we believe will be a game-changing drug for the treatment of bartonella and Lyme, made possible by this joint-development effort involving some of the smartest folks from academia, the private sector, and the non-profit world.  First, we plan to demonstrate in the test tube that we can eradicate these bacteria after they’ve infected cells. If all goes well, then it’s on to an animal study, and from there, human trials. This project has been funded by Bay Area Lyme Foundation, an organization which leads the fight against Lyme disease by funding research with a goal to put an end to this pandemic. We are also funded by our publicly announced co-funding partnership with Lyme Connection, a premier non-profit Lyme foundation under the auspices of the Town of Ridgefield, CT. Unlike general pool donations where you don’t know where your donation is going, with our co-funding effort, the following link specifically directs that donations go toward developing this new drug:  Click on link to Make a Tax Deductible Donation to Fund Our Research:  https://co.clickandpledge.com/sp/d1/default.aspx?wid=134576

A big thank you to our newest research funding partner, RescueRenovations.
​
They do general contracting and mold abatement and will donate 5% of any job to our research if you mention donating to Project Bartonella. You can contact them at RescueRenovations.net and if you know of another company that also wants to become a research funding partner, please let us know.

More on Dr. Phillips:  https://madisonarealymesupportgroup.com/2017/10/04/dr-steven-phillips-writing-book-on-lyme-and-bartonella-treatment/

https://madisonarealymesupportgroup.com/2016/07/11/dr-phillips-completely-trounces-cdc/

https://madisonarealymesupportgroup.com/2016/07/01/unedited-interview-with-dr-phillips-fox-5-ny/

https://madisonarealymesupportgroup.com/2016/04/03/dr-phillips-does-it-again/

 

Doctors, Public, Left in the Dark on Danger to Babies (From Lyme)

https://www.thechronicleherald.ca/opinion/doctors-public-left-in-the-dark-on-danger-to-babies-270535/

Dec. 21, 2018

The Chronicle Herald

OPINION: Doctors, public left in the dark on danger to babies

Jane Bailey

The following statement is false. You can only get Lyme disease from a black-legged tick. The next two statements are true. You can pass Lyme disease to your unborn baby. Your baby can suffer very serious adverse outcomes, including from miscarriage, stillbirth, and newborn death, as well as serious neurological development issues, and various other illnesses and developmental delays/issues as a result of Lyme infection during pregnancy.

Earlier this fall, on Nov. 12, a new, peer reviewed research article was published in the highly reputable science and medical journal PLOS ONE. It was authored by several senior Public Health Agency of Canada (PHAC) scientists and one Centers for Disease Control and Prevention (CDC) scientist. The paper unequivocally acknowledged mother-to-fetus (transplacental) transmission of Lyme disease as a fact.

This newly published paper also looked at case reports and studies from the past 30-plus years and found that there was a significant statistical difference in adverse outcomes for baby if the mother was infected with Lyme and had been untreated during pregnancy.

In their meta-analysis of several studies, 50 per cent of untreated women experienced fetal adverse outcomes compared to 11 per cent of treated women. In those cases, the authors state:

“Across 59 cases, negative outcomes for the fetus or newborn occurred in 61 per cent of pregnancies … (they) ranged from spontaneous miscarriage … fetal death and stillbirth … and death shortly following birth … to a range of congenital abnormalities and health issues.“

This is beyond alarming. It is an extremely important paper. And yet, not a word in the press, or notification to our doctors, nor, most importantly, to the public.

As far back as 1986, both the World Health Organization (WHO) and the CDC acknowledged mother-to-fetus transmission, and warned of possible adverse outcomes for baby. In June 1988, Health Canada released its own report acknowledging the same thing.

Nobody did anything. The information just sat there, hiding in plain sight.

In the summer of this year, the federal parliament of France, the Assemblée Nationale, issued a statement from the minister of health acknowledging mother-to-fetus transmission of Lyme disease.

And the WHO, after almost 10 years of considering the evidence, earlier this year (June 2018) issued a new International Classification of Diseases (ICD) code for congenital Lyme borreliosis (meaning babies born with Lyme disease) for physicians around the world. But on Monday (Dec. 17), the new WHO ICD-11 code for congenital Lyme borreliosis was the only code to be suddenly deleted from more than 55,000 new ICD-11 codes. At this point, it’s unclear why.

Something very strange and very unsettling is happening.

Where is Canada on this issue? Why isn’t Health Canada and the Public Health Agency of Canada saying anything? Why aren’t our public health departments and health authorities notifying doctors, women and parents-to-be of this very important issue? There should be national outrage over this appalling state of affairs regarding the non-notification of mother-to-fetus infection of Lyme disease. It is, actually, scandalous that the authorities have kept this from the public.

This mode of transmission changes everything.

Since 2014, I have corresponded on many Lyme issues with Dr. Robert Strang, chief medical officer for Nova Scotia, and Dr. Todd Hatchette, chief microbiologist for the Nova Scotia Health Authority and an infectious diseases doctor. They either denied that transplacental Lyme disease exists, or they refused to discuss it with me. They have both been provided with much of the 30-plus years of evidence, the same evidence considered by the scientists in the PLOS ONE article, the same evidence considered by the WHO, the CDC and PHAC.

At a meeting I attended at the Department of Health and Wellness on Sept. 1, 2016, I even had autopsy reports and photographs of babies with unequivocal evidence of the Lyme disease bacteria in their tissues and organs — everybody at the table declined to look at this evidence. As difficult and heartbreaking as such material is, this kind of behaviour from a department responsible for our health is unacceptable, and contributes to perpetuating the problem of no action.

It has been suggested by me, many times, that our doctors, and the public, be notified of the fact of mother-to-baby transmission of Lyme disease. All of my requests have been refused. On May 31, 2016, I was even told by Strang,

“I will no longer be responding to inquiries from you.”

It is despicable that the alarm has not been raised. And by not doing so, it could be argued, much unnecessary pain and suffering has been caused to many women, parents and children.

In a recent email (Oct. 23) Strang wrote to me regarding the above PLOS ONE research article, he stated,

“As you may be aware from the recent Lyme Hope meeting with PHAC, our national Public Health Agency has recently completed a comprehensive review of the evidence on Lyme disease in pregnancy. This review is undergoing peer review as part of possible publication. My public health practice will certainly follow the outcomes of this work.”

What Strang did not know when he sent me that email was that I was actually at that meeting with Lyme Hope and PHAC on Oct. 5 in Ottawa. I advised Strang of this fact, and of the fact that the scientists around the table, as well as one MD at that meeting, plus two MDs on the phone (a pediatric Lyme disease specialist, and an internal medicine specialist), the president of PHAC, and the director of the Infectious Diseases Branch, PHAC, all agreed that transplacental transmission was possible. Strang’s next response to me was, “I will not engage in an ongoing dialogue with you regarding this issue.” Appalling!

Strang is now silent on this issue. He has not made any public statement since the publication of the research article, neither has he responded to my last article on Lyme disease (“Lyme disease tunnel vision: Provincial authorities must expand horizons, review medial evidence”) published by The Chronicle Herald on Nov. 3. Why this silence? There is no getting around this, no “positive spin” can be put on this. The public, and our doctors, need to know. Shame on him. He, too, has the suffering of many on his conscience; or he should have.

With regard to mother-to-baby Lyme disease, doctors and women should know that babies and children present with symptoms very differently from adults.

For those of you reading who may have concerns regarding possible transplacental (mother-to-child) transmission of Lyme disease, I would direct you to the LymeHope.ca resources web-page. There you will find many credible and reputable resources and evidence that you can use to take to your doctor and discuss your concerns.

Jane Bailey lives in Wolfville. She has science and education diplomas and is a member of The Royal Society for Public Health.

__________________

**Comment**

AMEN!

PLOS ONE article:  https://madisonarealymesupportgroup.com/2018/12/12/systematic-review-on-gestational-lyme/

For more:  https://madisonarealymesupportgroup.com/2018/06/19/33-years-of-documentation-of-maternal-child-transmission-of-lyme-disease-and-congenital-lyme-borreliosis-a-review/

https://madisonarealymesupportgroup.com/2018/02/26/transplacental-transmission-fetal-damage-with-lyme-disease/

https://madisonarealymesupportgroup.com/2018/05/24/new-berlin-mom-given-life-altering-lyme-disease-diagnoses-after-pregnancy/

https://madisonarealymesupportgroup.com/2018/08/16/why-do-officials-continue-to-deny-gestational-lyme/

https://madisonarealymesupportgroup.com/2018/07/24/congenital-transmission-of-lyme-myth-or-reality/

https://madisonarealymesupportgroup.com/2018/10/05/canada-acknowledges-maternal-fetal-transmission-of-lyme-disease/

https://madisonarealymesupportgroup.com/2018/11/11/gestational-lyme-other-tick-borne-diseases-dr-jones/

https://madisonarealymesupportgroup.com/2018/08/16/why-do-officials-continue-to-deny-gestational-lyme/

https://madisonarealymesupportgroup.com/2017/10/15/pregnancy-in-lyme-dr-ann-corson/